Advanced Search

Study Preview



Study Title and Description

Efficacy and safety of 12 weeks of elbasvir ± grazoprevir ± ribavirin in participants with hepatitis C virus genotype 2, 4, 5 or 6 infection: The C-SCAPE study.



Key Questions Addressed
6 Key Question 6. What is the effectiveness of currently recommended antiviral treatments in improving health outcomes in patients with HCV infection?
  • Comments Comments (
    0
    ) |

Primary Publication Information
  • Comments Comments (
    0
    ) |
TitleData
Title Efficacy and safety of 12 weeks of elbasvir ± grazoprevir ± ribavirin in participants with hepatitis C virus genotype 2, 4, 5 or 6 infection: The C-SCAPE study.
Author Brown A., Hézode C., Zuckerman E., Foster GR., Zekry A., Roberts SK., Lahser F., Durkan C., Badshah C., Zhang B., Robertson M., Wahl J., Barr E., Haber B.
Country Imperial College Healthcare NHS Trust, London, UK.
Year 2018
Numbers Pubmed ID: 29152828

Secondary Publication Information
There are currently no secondary publications defined for this study.


Extraction Form: Key Questions 1-9


Results & Comparisons

No Results found.